11 Other financial assets
|
|
Loans associates and joint ventures |
|
Other participating interests |
|
Other receivables |
|
Other |
|
Total |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Balance at 1 January 2021 |
|
4 |
|
219 |
|
83 |
|
9 |
|
315 |
|
|
|
|
|
|
|
|
|
|
|
Changes: |
|
|
|
|
|
|
|
|
|
|
- Charged to the income statement |
|
- |
|
- |
|
(14) |
|
(2) |
|
(16) |
- Disposals |
|
- |
|
(123) |
|
- |
|
- |
|
(123) |
- Capital payments |
|
- |
|
35 |
|
- |
|
- |
|
35 |
- Loans granted/prepayments |
|
- |
|
- |
|
10 |
|
- |
|
10 |
- Repayments/(receipts) |
|
- |
|
- |
|
(31) |
|
1 |
|
(30) |
- Exchange differences |
|
- |
|
- |
|
3 |
|
- |
|
3 |
- Transfers |
|
(3) |
|
14 |
|
(20) |
|
(4) |
|
(13) |
- Changes in fair value |
|
- |
|
46 |
|
- |
|
- |
|
46 |
Balance at 31 December 2021 |
|
1 |
|
191 |
|
31 |
|
4 |
|
227 |
|
|
|
|
|
|
|
|
|
|
|
Changes: |
|
|
|
|
|
|
|
|
|
|
- Charged to the income statement |
|
- |
|
- |
|
1 |
|
(1) |
|
- |
- Disposals |
|
- |
|
(24) |
|
- |
|
- |
|
(24) |
- Capital payments |
|
- |
|
28 |
|
- |
|
- |
|
28 |
- Loans granted/prepayments |
|
1 |
|
- |
|
127 |
|
- |
|
128 |
- Repayments/(receipts) |
|
- |
|
- |
|
1 |
|
3 |
|
4 |
- Exchange differences |
|
- |
|
- |
|
(7) |
|
- |
|
(7) |
- Transfers |
|
- |
|
- |
|
16 |
|
- |
|
16 |
- Changes in fair value |
|
- |
|
(66) |
|
- |
|
- |
|
(66) |
- Expected credit loss (ECL) adjustment and impairments |
|
- |
|
- |
|
(11) |
|
- |
|
(11) |
- Reclassification from/to held for sale |
|
- |
|
(4) |
|
- |
|
- |
|
(4) |
- Other changes |
|
- |
|
- |
|
- |
|
4 |
|
4 |
Balance at 31 December 2022 |
|
2 |
|
125 |
|
158 |
|
10 |
|
295 |
‘Disposals’ includes the divestment by DSM Venturing of its share in Natreon Inc. (€18 million) and S-Biomedic N.V. (€6 million).
‘Loans granted’ reflects a loan granted to Amyris, Inc. (€77 million) and Brains Bioceutical Corp. (€20 million) and to other participating interests held by DSM Venturing.
‘Changes in fair value’ consists mainly of the value decrease of our minority share in Amyris, Inc. (-€56 million). These changes are posted to the Fair value reserve in Other comprehensive income.
